Raising a Series B or later in medtech.
Later medtech rounds fund the commercial launch after clearance or approval. Investors check adoption, reimbursement and manufacturing at scale.
Medtech
Medtech investors fund a device through three gates: a regulatory pathway, clinical evidence and a way to get paid. Your FDA route sets how much capital you need and how long it takes.
What later-stage investors expect in medtech
By Series B the conversation shifts from approval to adoption.
Early commercial traction
- Hospitals buying and reordering, not one-off evaluations
- Physicians using it in routine cases
- Sales per rep that point to a scalable team
Reimbursement that holds
- Coverage decisions from major payers
- A billing code that fits, or a plan to secure one
- Evidence of lower cost or better outcomes
Manufacturing at scale
- Cost per unit falling with volume
- Supply chain with backup suppliers
- A clean quality record and no open recalls
How the round comes together
Later medtech rounds are led by larger health care venture and growth funds.
- 1 · A larger fund leads
- 2 · Insiders follow
- 3 · Strategics and families
Multi-stage VCs
Often leads
Health care venture and growth funds lead most later device rounds.
Corporate VCs
Sometimes
Device makers invest once sales show the product fits their portfolio.
Family offices
Sometimes
Families take larger positions once the device is on the market.
Pre-seed & seed funds
Now and then
Early investors may keep a small pro-rata.
Preferences start to matter
Later rounds bring larger checks and negotiated terms. Many medtech exits are sales to device makers, so liquidation preferences decide who gets paid first. Model the outcome at several sale prices.
The slides investors read first
Adoption
Accounts, reorders and procedures per month.
Reimbursement
Coverage won and what is still pending.
Evidence
Real-world outcomes since launch.
Operations
Unit cost, supply and quality record.
The plan
What the round buys and the path to profit.
Questions founders ask
Why is reimbursement so important after clearance?
Clearance lets you sell, but hospitals and physicians need to be paid for using your device. Without coverage, adoption stalls even when the device works.
Should I build a sales team or partner with a distributor?
It depends on your call point and margins. Investors want to see you tested one approach and know what each sale costs.
Sources
Sources: FDA guidance on device classification, 510(k), De Novo and PMA pathways; CMS coverage and coding resources; investors' published criteria. Editorial content, reviewed quarterly. Not financial, legal or medical advice.
Other stages
Related sectors
Who funds this round
Learn the terms
Run the numbers
Raise in your city
Inside Unicorn Factory
Free account
Investor matching is coming to your free account. Create it now and we will match your round the day it opens. Until then, get an honest read on your deck.